Back to Search
Start Over
Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT
- Source :
- Regenerative Therapy
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
- Subjects :
- Ruxolitinib
Acute graft-versus-host disease
biology
business.industry
T cell
Biomedical Engineering
Allo hsct
Acute lymphoblastic leukemia
medicine.disease
Chimeric antigen receptor
CD19
Biomaterials
Graft-versus-host disease
medicine.anatomical_structure
Immunology
Acute graft versus host disease
medicine
biology.protein
Donor derived
business
Letter to the Editor
Developmental Biology
medicine.drug
Subjects
Details
- ISSN :
- 23523204
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Regenerative Therapy
- Accession number :
- edsair.doi.dedup.....afc67b7eeaf6c8f9f1036c4f9c52b290
- Full Text :
- https://doi.org/10.1016/j.reth.2019.06.006